Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Date publication

août 2003

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/12885807

Résumé

This randomized, 2 x 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as adjuvant treatment of patients with stage II (Dukes' B2) and III (Dukes' C) colon cancer.

Mots clés

Adenocarcinoma, drug therapy, Adult, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Chemotherapy, Adjuvant, Chi-Square Distribution, Colonic Neoplasms, drug therapy, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, administration & dosage, Humans, Infusions, Intravenous, Leucovorin, administration & dosage, Male, Middle Aged, Prognosis, Proportional Hazards Models, Survival Analysis, Treatment Outcome

Référence

J. Clin. Oncol.. 2003 Aug;21(15):2896-903